Results 181 to 190 of about 12,025 (204)

Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus

Pulmonary Pharmacology & Therapeutics, 2018
Long-acting muscarinic antagonists (LAMAs) have been recommended for the treatment of chronic obstructive pulmonary disease and (more recently) asthma. However, the in vitro pharmacological profiles of the four LAMAs currently marketed (tiotropium, umeclidinium, aclidinium and glycopyrronium) have not yet been compared (relative to ipratropium) by ...
Naline, Emmanuel, Grassin Delyle, Stanislas, Salvator, Hélène, Brollo, Marion, Faisy, Christophe, Victoni, Tatiana, Abrial, Charlotte, Devillier, Philippe   +7 more
openaire   +4 more sources

Discovery of Biphenyl Piperazines as Novel and Long Acting Muscarinic Acetylcholine Receptor Antagonists

Journal of Medicinal Chemistry, 2008
A series of novel biphenyl piperazines was discovered as highly potent muscarinic acetylcholine receptor antagonists via high throughput screening and subsequent optimization. Compound 5c with respective 500- and 20-fold subtype selectivity for M3 over M2 and M1 exhibited excellent inhibitory activity and long duration of action in a ...
Jian, Jin, Brian, Budzik, Yonghui, Wang, Dongchuan, Shi, Feng, Wang, Haibo, Xie, Zehong, Wan, Chongye, Zhu, James J, Foley, Edward F, Webb, Manuela, Berlanga, Miriam, Burman, Henry M, Sarau, Dwight M, Morrow, Michael L, Moore, Ralph A, Rivero, Michael, Palovich, Michael, Salmon, Kristen E, Belmonte, Dramane I, Lainé   +19 more
openaire   +2 more sources

The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD

Pulmonary Pharmacology & Therapeutics, 2010
Bronchodilators are the cornerstone of pharmacological management of COPD. For patients whose conditions are not sufficiently controlled by monotherapy, combining bronchodilators of different classes, in particular an inhaled muscarinic antagonist with an inhaled beta(2)-agonist, seems a convenient way of delivering treatment and obtaining superior ...
CAZZOLA, MARIO, Molimard, M.
openaire   +3 more sources

Long-acting muscarinic M3 receptor antagonists.

Expert opinion on therapeutic patents, 2010
A series of 10 closely related patent applications define Theravance's approach to the development of long-acting M(3) selective antagonists for the treatment of chronic obstructive pulmonary disease. The applications illustrate a modular approach to the design of such agents, comprising a muscarinic pharmacophore attached to a second, less ...
openaire   +2 more sources

Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study

Chest, 2021
Chen-Liang Tsai, Yu-Juei Hsu, Meng-Ting Wang   +2 more
exaly  

Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.

Current opinion in investigational drugs (London, England : 2000), 2009
Aclidinium bromide is a novel, inhaled, long-acting antimuscarinic agent being developed by Almirall Prodesfarma SA and Forest Laboratories Inc as a once-daily treatment for COPD. In preclinical studies, aclidinium bromide demonstrated a comparable profile to tiotropium bromide, with a slightly quicker onset of action but shorter duration of action ...
openaire   +2 more sources

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

Chronic Respiratory Disease, 2023
Shigeo Muro, Kazuya Tanimura, Yukio Fujita   +2 more
exaly  

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Respiratory Medicine, 2010
Y Fukuchi
exaly  

NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease, 2011
Claus Vogelmeier, Donald Banerji
exaly  

Tiotropium bromide, a long acting muscarinic receptor antagonist triggers intracellular calcium signalling in the heart

Toxicology and Applied Pharmacology, 2019
Shabana Cassambai, Afthab Hussain, Derek Renshaw   +2 more
exaly